Leonard L. Mazur - 08 Aug 2025 Form 4 Insider Report for Citius Pharmaceuticals, Inc. (CTXR)

Signature
/s/ Alexander M. Donaldson, by power of attorney
Issuer symbol
CTXR
Transactions as of
08 Aug 2025
Net transactions value
$0
Form type
4
Filing time
23 Sep 2025, 16:05:24 UTC
Previous filing
16 Dec 2024
Next filing
01 Dec 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mazur Leonard L Chief Executive Officer, Director C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD /s/ Alexander M. Donaldson, by power of attorney 23 Sep 2025 0001463414

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CTXR Common Stock 410,214 08 Aug 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTXR Warrant to Purchase Common Stock Disposed to Issuer -125,490 -100% 0 08 Aug 2025 Common Stock 125,490 $28.75 Direct F1
transaction CTXR Warrant to Purchase Common Stock Award +125,490 125,490 08 Aug 2025 Common Stock 125,490 $28.75 Direct F1
transaction CTXR Warrant to Purchase Common Stock Disposed to Issuer -89,388 -100% 0 08 Aug 2025 Common Stock 89,388 $19.25 Direct F2
transaction CTXR Warrant to Purchase Common Stock Award +89,388 89,388 08 Aug 2025 Common Stock 89,388 $19.25 Direct F2
holding CTXR Stock Option (Right to Purchase Common Stock) 24,000 08 Aug 2025 Common Stock 24,000 $9.50 Direct F3
holding CTXR Stock Option (Right to Purchase Common Stock) 22,000 08 Aug 2025 Common Stock 22,000 $17.50 Direct F4
holding CTXR Stock Option (Right to Purchase Common Stock) 22,000 08 Aug 2025 Common Stock 22,000 $31.25 Direct F5
holding CTXR Stock Option (Right to Purchase Common Stock) 26,000 08 Aug 2025 Common Stock 26,000 $51.00 Direct F6
holding CTXR Stock Option (Right to Purchase Common Stock) 12,000 08 Aug 2025 Common Stock 12,000 $50.00 Direct F6
holding CTXR Stock Option (Right to Purchase Common Stock) 8,000 08 Aug 2025 Common Stock 8,000 $25.25 Direct F6
holding CTXR Stock Option (Right to Purchase Common Stock) 7,000 08 Aug 2025 Common Stock 7,000 $16.75 Direct F6
holding CTXR Stock Option (Right to Purchase Common Stock) 6,000 08 Aug 2025 Common Stock 6,000 $40.50 Direct F6
holding CTXR Stock Option (Right to Purchase Common Stock) 1,600 08 Aug 2025 Common Stock 1,600 $86.25 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from August 14, 2025 to August 14, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on August 13, 2018 and was exercisable immediately.
F2 The two reported transactions involved an amendment of an outstanding warrant to extend the termination date from September 27, 2025 to September 27, 2026, which resulted in the cancellation of the "old" warrant and the grant of a replacement warrant. The warrant was originally issued on September 27, 2019 and was exercisable immediately.
F3 The options were granted on November 7, 2024. The options vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F4 The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F5 The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company as of each such vesting date.
F6 The options are vested in full and exercisable immediately.

Remarks:

All share amounts reflect the 1-for-25 reverse stock split effective November 22, 2024.